Search results for "Adenocarcinoma"

showing 10 items of 589 documents

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic aden…

2020

Abstract Background Chemotherapy is effective in metastatic pancreatic adenocarcinoma (mPA), but new approaches are still needed to improve patients' survival and quality of life. We have previously published good efficacy and tolerability results on a sequential treatment strategy of gemcitabine followed by an intensified FOLFIRI (5FU+irinotecan) regimen. In the present study, we evaluated the same sequence but replaced gemcitabine by the new gemcitabine + nab-paclitaxel standard first-line combination. Patients and methods We randomised chemotherapy-naive patients with proven mPA, bilirubin levels ≤1.5 upper limit of normal values and performance status 0–2 to alternately receive gemcitab…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyPaclitaxelPopulationLeucovorinPhases of clinical researchAdenocarcinomaNeutropeniaIrinotecanDeoxycytidineGastroenterology03 medical and health sciences0302 clinical medicineAlbuminsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasiseducationAgededucation.field_of_studyDrug Substitutionbusiness.industryMiddle Agedmedicine.diseaseGemcitabineNeoadjuvant TherapyProgression-Free SurvivalGemcitabinePancreatic NeoplasmsIrinotecanTreatment Outcome030104 developmental biologyOncologyTolerability030220 oncology & carcinogenesisDisease ProgressionFOLFIRICamptothecinFemaleFluorouracilFrancebusinessFebrile neutropeniamedicine.drugEuropean Journal of Cancer
researchProduct

Serum prolactin and tumors of the prostate: unchanged basal levels and lack of correlation to serum testosterone

1980

To investigate the possible role of circulatory levels of prolactin on the development of prostatic tumors, and to gain insight into the prolactin-androgen relationship, serum prolactin and testosterone were determined in 73 patients with newly diagnosed prostatic adenocarcinoma. Controls consisted of 32 patients with benign prostatic hyperplasia before treatment, 19 age-matched controls, and 21 young individuals. Hormones were measured under standardized conditions by highly specific and sensitive radioimmunoassays. There was no difference in prolactin in the elderly men regardless of prostate pathology, but a significant increment was found in young controls. Individual prolactin values d…

AdultMaleAgingendocrine systemmedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismProstatic HyperplasiaStimulationAdenocarcinomaProstate cancerEndocrinologyProstateInternal medicineHumansMedicineTestosteroneAgedbusiness.industryProstatic NeoplasmsRadioimmunoassayMiddle AgedHyperplasiamedicine.diseaseAndrogenProlactinProlactinEndocrinologymedicine.anatomical_structurebusinesshormones hormone substitutes and hormone antagonistsHormoneJournal of Endocrinological Investigation
researchProduct

Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer

2005

Abstract BACKGROUND AND AIMS: oxaliplatin in combination with folinic acid (FA) and infusional 5-fluorouracil (5-FU) has shown significant anti-tumor activity in gastric cancer patients (FOLFOX). Previous studies have shown that gemcitabine (GEM), a new fluorinated anti-metabolite, enhances the individual anti-tumor activity of either 5-FU or oxaliplatin. We have therefore designed a multi-center phase II trial in order to test a novel GEM+FOLFOX-4 regimen in patients with metastatic gastric cancer. METHODS: we enrolled 36 patients, 28 males and 8 females, with an average age of 64.4 years (range 37-78), who received bi-weekly treatment with GEM (1,000 mg/m2 on day 1), levo-FA (100 mg/m2 on…

AdultMaleAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyOrganoplatinum CompoundsGastrointestinal Diseasesmedicine.drug_classfolinic acidmedicine.medical_treatmentLeucovorinAdenocarcinomaToxicologyDeoxycytidineAntimetaboliteGastroenterologyFolinic acidFOLFOXStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumans5-fluorouracilPharmacology (medical)Infusions IntravenousAgedNeoplasm StagingPharmacologyChemotherapybusiness.industrygastric canceroxaliplatingemcitabineMiddle AgedHematologic DiseasesGemcitabineSurgeryOxaliplatinSurvival RateRegimenOncologyFluorouracilFemaleNeurotoxicity SyndromesFluorouracilbusinessmedicine.drugCancer Chemotherapy and Pharmacology
researchProduct

Expression of nm23 in gastric carcinoma: association with tumor progression and poor prognosis.

1998

BACKGROUND Expression of nm23 has been shown to be inversely correlated with the metastatic potential of several human cancers. In the current study, the expression and prognostic impact of nm23 was immunohistochemically studied in 413 curatively resected gastric carcinomas. METHODS Tumor sections of the 413 gastric carcinomas were stained with a polyclonal antibody that was raised against the nm23-H1/NDP kinase A, which is identical to the nm23-H1 gene product. RESULTS Expression of nm23 was detected in 84.5% (n = 349) of all tumors, in the majority of cases (71.2%) causing a homogeneous staining reaction in more than 75% of tumor cells. Expression of nm23 was positively correlated with th…

AdultMaleCancer ResearchMetastasisAntigens NeoplasmStomach NeoplasmsLymphatic vesselBiomarkers TumorMedicineHumansLymph nodeAgedMonomeric GTP-Binding ProteinsAged 80 and overbusiness.industryStomachCarcinomaCancerMiddle AgedNM23 Nucleoside Diphosphate Kinasesmedicine.diseasePrognosisSurvival Analysismedicine.anatomical_structureOncologyTumor progressionNucleoside-Diphosphate KinaseCancer researchAdenocarcinomaImmunohistochemistryFemalebusinessCarcinoma Signet Ring CellTranscription FactorsCancer
researchProduct

Prognostic Value of Immunohistochemical Expression of Beta-1 Integrin in Pancreatic Carcinoma

1999

<i>Background: </i>Prognostically relevant factors based on the histological assessment of the resected pancreas are known. However, the knowledge of additional factors associated with the prognosis is helpful in planning the therapy for an individual patient. β<sub>1</sub> Integrin expression is known to have a prognostic influence in some malignant tumors. No data are, however, available on the prognostic value of β<sub>1</sub> integrins in pancreatic carcinoma. <i>Method: </i>We investigated paraffin-embedded specimens of 19 patients undergoing surgical treatment for periampullary carcinoma and of 42 patients for ductal pancreatic carcinoma…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyPancreatic diseaseIntegrinFlow cytometryPredictive Value of TestsBeta 1 integrinHumansMedicineAgedNeoplasm StagingAged 80 and overmedicine.diagnostic_testbiologybusiness.industryCell adhesion moleculeIntegrin beta1CarcinomaGeneral MedicineMiddle AgedPrognosismedicine.diseaseImmunohistochemistryGene Expression Regulation NeoplasticPancreatic Neoplasmsmedicine.anatomical_structureOncologyLymphatic Metastasisbiology.proteinAdenocarcinomaImmunohistochemistryFemalebusinessPancreasOncology
researchProduct

Etoposide, doxorubicin (Adriamycin) and cisplatin regimen in advanced gastric adenocarcinoma: experience with a lower dose schedule

1994

A phase II trial of etoposide (100 mg/m2) on days 4, 5, 6, doxorubicin (Adriamycin, 20 mg/m2) on days 1, 7, and cisplatin (30 mg/m2) on days 2, 8 (EAP) was carried out in order to reduce toxicity associated with a full-dose EAP regimen for advanced and/or metastatic gastric adenocarcinoma. Out of 21 evaluable patients, 2 (10%) had a complete response (CR), 7 (33%) had a partial response (PR), 4 (20%) showed no change and 8 progressed (38%). The mean duration of response (CR+PR) was 8.4+ months. Survival of the whole group was 7.5+ months. Treatment was quite well tolerated by most patients on an outpatient basis. Grade 3 vomiting and leukopenia were seen in 30% and 35% of cases respectively…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentmedicine.medical_treatmentAdenocarcinomaGastroenterologyDrug Administration ScheduleStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChemotherapyEtoposideAgedEtoposideCisplatinChemotherapyLeukopeniabusiness.industryStomachGeneral MedicineMiddle Agedmedicine.diseaseEAPSurgeryRegimenmedicine.anatomical_structureOncologyDoxorubicinVomitingAdenocarcinomaFemaleCisplatinmedicine.symptomGastric cancerbusinessmedicine.drugJournal of Cancer Research and Clinical Oncology
researchProduct

Cytochrome P450 2E1 variable number tandem repeat polymorphisms and health risks: A genotype-phenotype study in cancers associated with drinking and/…

2012

Cytochrome P450 2E1 (CYP2E1) is one of the main enzymes involved in the oxidation of ethanol and in the transformation of a number of potentially dangerous compounds. It has various polymorphic sites, one of which is a variable number tandem repeat (VNTR) polymorphism previously described in the 5'-flanking region. The aim of this study was to investigate the genotype-phenotype association between CYP2E1 VNTR polymorphisms and risky health habits in healthy subjects and to analyze the associations between these polymorphisms with drinking- and/or smoking-related cancers. We analyzed 166 healthy subjects by genotyping for the CYP2E1 VNTR polymorphism associated with drinking and/or smoking h…

AdultMaleCancer Researchmedicine.medical_specialtyCarcinoma HepatocellularAlcohol Drinkinghuman genetic variability genetic factors cytochrome P450 2E1 variable number tandem repeat polymorphisms predis-posing alleles health risks drinking- and/or smoking-related cancer.Minisatellite RepeatsBiologyBiochemistryGastroenterologyRestriction fragmentYoung AdultRisk-TakingRisk FactorsInternal medicineGenotypeOdds RatioGeneticsmedicineHumansGenetic Predisposition to DiseaseMolecular BiologyGenotypingGenetic Association StudiesGeneticsPolymorphism GeneticLiver NeoplasmsSmokingCytochrome P-450 CYP2E1Odds ratiomedicine.diseaseConfidence intervalPancreatic NeoplasmsVariable number tandem repeatSettore BIO/18 - GeneticaOncologyCase-Control StudiesHepatocellular carcinomabiology.proteinMolecular MedicineAdenocarcinomaFemalePolymorphism Restriction Fragment Length
researchProduct

Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer

2011

BACKGROUND: Preoperative chemoradiation is becoming the standard treatment for patients with locally advanced rectal cancer. However, since the introduction of total mesorectal excision (TME), local recurrence rates have been reduced significantly, and some patients can be spared from potentially toxic over treatment. The current study was designed to assess the factors that predict recurrence in an institutional series of patients with rectal cancer who had clinical T2 lymph node-positive (cT2N+) tumors or cT3N0/N+ tumors and underwent radical surgery without receiving preoperative chemoradiation. METHODS: Between November 1997 and November 2008, the authors' multidisciplinary group preope…

AdultMaleCancer Researchmedicine.medical_specialtyColorectal cancermedicine.medical_treatmentAdenocarcinomaDisease-Free SurvivalmedicineHumansRadical surgerySurvival rateAgedNeoplasm StagingMesorectalAged 80 and overRectal Neoplasmsbusiness.industryStandard treatmentCancerMiddle Agedmedicine.diseaseCombined Modality TherapyTotal mesorectal excisionNeoadjuvant TherapySurgerySurvival RateRadiation therapyTreatment OutcomeOncologyLymphatic MetastasisFemaleNeoplasm Recurrence LocalbusinessCancer
researchProduct

Expression of CD44 variant proteins in adenocarcinoma of Barrett's esophagus and its relation to prognosis

1998

BACKGROUND None of the commonly used staging criteria accurately determine the prognosis of a patient with adenocarcinoma of Barrett's esophagus. The authors therefore assessed the expression pattern and prognostic impact of CD44 standard and CD44 isoforms CD44v4, v5,v6,v7, and v10 in adenocarcinoma of Barrett's esophagus. METHODS Specimens from 41 patients with adenocarcinoma of Barrett's esophagus who underwent esophageal resection were embedded in paraffin and studied immunohistochemically to determine the expression of CD44 splice variants. Histomorphologic parameters and survival time were not known at the time of the investigation. RESULTS Correlations between favorable clinical or hi…

AdultMaleCancer Researchmedicine.medical_specialtyEsophageal NeoplasmsAdenocarcinomaGastroenterologyBarrett EsophagusAntigens NeoplasmInternal medicineBiopsymedicineHumansEsophagusAgedGlycoproteinsAnalysis of Variancebiologymedicine.diagnostic_testbusiness.industryEsophageal diseaseCD44CancerMiddle Agedmedicine.diseasedigestive system diseasesHyaluronan Receptorsmedicine.anatomical_structureOncologyBarrett's esophagusbiology.proteinAdenocarcinomaFemaleComplicationbusinessCancer
researchProduct

Comparison of Different Nodal Staging in Patients With Locally Advanced Mid-low Rectal Cancer After Long-term Neoadjuvant Chemoradiation Therapy.

2019

Background/Aim: The aim of this study was to compare the ability of different lymph nodal staging systems to predict cancer recurrence in a multicenter European series of patients who underwent proctectomy after neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Patients and Methods: Data on 170 consecutive patients undergoing proctectomy after neoadjuvant therapy for cT3-4 or cN+ rectal adenocarcinoma were retrieved from the European MRI and Rectal Cancer Surgery database. The prognostic role of the number of retrieved and examined nodes, nodal ratio, and log odds of positive lymph nodes (LODDS) was analyzed and compared by receiver operating characteristic curves, Pearson t…

AdultMaleCancer Researchmedicine.medical_specialtyMultivariate analysisColorectal cancerDisease-free survivalmedicine.medical_treatmentLODDSLocally advancedAdenocarcinomaDisease-Free SurvivalLog odds of positive lymph nodeRectal AdenocarcinomaMedicineHumansRectal cancerLog odds of positive lymph nodesNeoadjuvant therapyAgedNeoplasm StagingAged 80 and overReceiver operating characteristicddc:617business.industryRectal NeoplasmsHazard ratioGeneral MedicineNodal ratioChemoradiotherapyMiddle Agedmedicine.diseasePrognosisConfidence intervalNeoadjuvant TherapyOncologydisease-free survival; lodds; log odds of positive lymph nodes; neoadjuvant therapy; nodal ratio; rectal cancer; adenocarcinoma; adult; aged; aged 80 and over; disease-free survival; female; humans; lymph nodes; male; middle aged; neoplasm recurrence Local; Neoplasm Staging; Prognosis; Rectal Neoplasms; Chemoradiotherapy; Neoadjuvant TherapyNeoadjuvant therapyFemaleRadiologyLymph NodesNeoplasm Recurrence LocalbusinessAnticancer research
researchProduct